Recursion Pharmaceuticals

Recent news

• BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
  Market Newswire · 2026/9/21
• Rating change
  Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $5
  Market Newswire · 2025/6/18
• Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3
  Market Newswire · 2026/8/17
• Rating change
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $6
  Market Newswire · 2026/2/26
• Rating change
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $8
  Market Newswire · 2025/5/7
• Rating change
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $7
  Market Newswire · 2025/12/9
• Rating change
  JPMorgan has upgraded Recursion (RXRX.US) to an 'Overweight' rating, with its core pipeline candidate REC-4881 expected to become a blockbuster drug.
  Zhitong Finance · 2025/12/18
• Rating change
  J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10
  Market Newswire · 2026/4/30
• Rating change
  J.P. Morgan Initiates Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Announces Target Price $11
  Market Newswire · 2025/12/17
• Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
  TipRanks · 2026/9/21
• Rating change
  Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5
  Market Newswire · 2025/6/17
• J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating
  Market Newswire · 2026/9/16
• Rating change
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $8
  Market Newswire · 2025/8/6
• Rating change
  Morgan Stanley Initiates Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Announces Target Price $5
  Market Newswire · 2025/12/9
• Rating change
  TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
  Market Newswire · 2026/8/6
• Rating change
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $7
  Market Newswire · 2026/1/14
• Rating change
  Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8
  Market Newswire · 2026/8/6
• BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $6
  Market Newswire · 2026/8/12
• Rating change
  TR | OpenAI - 4o Initiates Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Announces Target Price $6
  Market Newswire · 2025/8/6
• Rating change
  Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.5
  Market Newswire · 2026/5/14

Headlines are aggregated automatically and are not independently verified or edited by our team.